prix semaglutide france steps up monitoring of diabetes drug used for weight loss Acheter Rybelsus livraison rapide pas

Social Studio believes commitment to your creative process cultivates empathy and connection

Only about one-quarter of clinicians believe patients generally understand the long-term nature of GLP-1 therapy

Breaking News May 12, 2026 Pharma Now Editorial Team Novo Nordisk's STEP UP data, presented at the European Congress on Obesity (ECO) in Istanbul this week, signal a near-term formulation and supply challenge: a higher-dose semaglutide 7.2 mg presentation that outperforms the approved 2.4 mg dose will require manufacturers and CMOs to revisit fill-finish capacity, device compatibility, and cold-chain infrastructure before any commercial scale-up can follow a potential regulatory submission

The GLP-1 drugs have set a new standard for whats possible, while options like Contrave and orlistat still have a real place for the right patient

This docket runs parallel to existing GLP1 MDL litigation that addresses other injury types, such as gastrointestinal harms